北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia
作者: Chen, Huan; Liu, Kai-yan; Xu, Lan-ping; Liu, Dai-hong; Chen, Yu-hong; Zhao, Xiang-yu; Han, Wei; Zhang, Xiao-hui; Wang, Yu; Zhang, Yuan-yuan; Qin, Ya-zhen; Liu, Yan-rong; Huang, Xiao-jun
关键词: Philadelphia chromosome ; Acute lymphoblastic leukemia ; Allogeneic hematopoietic cell transplantation ; Minimal residual disease ; Imatinib
刊名: JOURNAL OF HEMATOLOGY & ONCOLOGY
发表日期: 2012-06-08
DOI: 10.1186/1756-8722-5-29
卷: 5
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Hematology
研究领域[WOS]: Oncology ; Hematology
关键词[WOS]: POLYMERASE-CHAIN-REACTION ; MARROW TRANSPLANTATION ; COMPLETE REMISSION ; CANCER PROGRAM ; CHEMOTHERAPY ; TRANSCRIPTS ; THERAPY ; RELAPSE ; REDUCTION ; INDUCTION
英文摘要:

Background: Maintenance therapy with imatinib during the post-transplant period has been used for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL); however, its efficacy has not been demonstrated. A study was designed to investigate the safety of imatinib and its efficacy in preventing hematological relapse and improving disease-free survival (DFS) when administered after allogeneic hematopoietic stem cell transplantation (allo-HCT).

Methods: Patients with Ph + ALL that received allo-HCT were enrolled in the study. Real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was used to detect BCR-ABL transcript levels. Imatinib therapy was initiated if patient neutrophil counts were > 1.0 x 10(9)/L and platelet counts were > 50.0 x 10(9)/L, or if they displayed either elevated BCR-ABL transcript levels in two consecutive tests, or a BCR-ABL transcript level >= 10(-2) after initial engraftment. Patients receiving imatinib after relapse were assigned to the non-imatinib group. The imatinib treatment was scheduled for 3-12 months, until BCR-ABL transcript levels were negative at least for three consecutive tests or complete molecular remission was sustained for at least 3 months.

Results: A total of 82 patients were enrolled. Sixty-two patients initiated imatinib therapy post-HCT. Imatinib therapy was initiated at a median time of 70 days post-HCT. Grade 3-4 adverse events (AEs) occurred in 17.7% of patients. Ten patients (16.1%) terminated imatinib therapy owing to AEs. Among the patients in imatinib and non-imatinib groups, the estimated 5-year relapse rate was 10.2% and 33.1% (p = 0.016), and the 5-year probability of DFS was 81.5% and 33.5% (p = 0.000) with the median follow-up of 31 months (range, 2.5-76 months) and 24.5 months (range, 4-72 months), respectively. Multivariate analysis identified imatinib maintenance therapy post-HCT as an independent prognostic factor for DFS (p = 0.000, hazard ratio [HR] = 4.8) and OS (p = 0.000, HR = 6.2).

Conclusions: These results indicate that relapse rate can be reduced and DFS may be improved in Ph + ALL patients with imatinib maintenance therapy after HCT. BCR-ABLmonitoring by qRT-PCR can guide maintenance therapy with imatinib including initiation time and treatment duration after allo-HCT.

语种: 英语
所属项目编号: 30971292 ; 2011AA020105
项目资助者: National Natural Science Foundation of China ; National High-tech R&amp ; D Program of China ; Ministry of Health of China
WOS记录号: WOS:000307009600001
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/53663
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Peoples Hosp, Inst Hematol, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China

Recommended Citation:
Chen, Huan,Liu, Kai-yan,Xu, Lan-ping,et al. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia[J]. JOURNAL OF HEMATOLOGY & ONCOLOGY,2012,5.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Chen, Huan]'s Articles
[Liu, Kai-yan]'s Articles
[Xu, Lan-ping]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Chen, Huan]‘s Articles
[Liu, Kai-yan]‘s Articles
[Xu, Lan-ping]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace